139 related articles for article (PubMed ID: 19522059)
1. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
Lyrdal D; Boijsen M; Suurküla M; Lundstam S; Stierner U
Nucl Med Commun; 2009 Jul; 30(7):519-24. PubMed ID: 19522059
[TBL] [Abstract][Full Text] [Related]
2. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397
[TBL] [Abstract][Full Text] [Related]
3. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V
BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690
[TBL] [Abstract][Full Text] [Related]
7. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
8. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
10. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
11. 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
Ambrosini V; Quarta C; Zinzani PL; Nanni C; Fini M; Torricelli P; Giavaresi G; D'Errico-Grigioni A; Malvi D; Franchi R; Fanti S
Q J Nucl Med Mol Imaging; 2010 Dec; 54(6):689-97. PubMed ID: 20639808
[TBL] [Abstract][Full Text] [Related]
12. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.
Kakizoe M; Yao M; Tateishi U; Minamimoto R; Ueno D; Namura K; Makiyama K; Hayashi N; Sano F; Kishida T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Taguri M; Morita S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2014 Jun; 14():390. PubMed ID: 24885730
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.
Minamimoto R; Nakaigawa N; Tateishi U; Suzuki A; Shizukuishi K; Kishida T; Miura T; Makiyama K; Yao M; Kubota Y; Inoue T
Clin Nucl Med; 2010 Dec; 35(12):918-23. PubMed ID: 21206220
[TBL] [Abstract][Full Text] [Related]
14. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
[TBL] [Abstract][Full Text] [Related]
15. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
17. Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
Martínez-Rodríguez I; Banzo I; Carril JM
Endocrine; 2013 Aug; 44(1):264-5. PubMed ID: 23564596
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Lalami Y; Garcia C; Flamen P; Ameye L; Paesmans M; Awada A
Head Neck; 2016 Mar; 38(3):347-54. PubMed ID: 25332069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
